• Adagio Medical reported 22 patients treated with its next-generation vCLAS Ultra ventricular ablation system across seven US and Canadian centers.
• Treatments included 19 FULCRUM-VT IDE sub-study participants and three compassionate-use cases; the study continues through operational restructuring.
• Early clinical experience disclosed in the update showed shorter ablation times and improved catheter performance versus the first-generation system, according to physicians.
• FDA review continues for the first-generation vCLAS system’s premarket approval application, submitted in May 2026.
• The board continues evaluating strategic alternatives to maximize shareholder value.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adagio Medical Holdings Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261110369510) on November 10, 2026, and is solely responsible for the information contained therein.